ArticleCureus2023
Prognostic Relationship Between the ABO Blood Groups and Metastatic Gastric Cancer.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Relationship between ABO blood group and lymph node metastasis in colon cancer: a retrospective cohort study.World journal of surgical oncology · 2026Observational
- Clinical and Histopathological Correlations With Blood Groups in Patients With Gastric Cancer.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimGastric cancer is one of the most common malignant tumors of the digestive system and has a poor prognosis. Since recurrence and distant metastasis are common in gastric cancer, it is important to use practical and reliable prognostic parameters. In this study, the prognostic relationship between the ABO blood groups and metastatic gastric cancer was investigated. METHOD AND MATERIAL: Data were collected by retrospectively scanning the files of 225 patients who were followed up with the diagnosis of metastatic gastric cancer in 2010-2022. The patients' demographic data (age, gender), tumor histopathology, tumor location, and ABO and Rh blood groups were evaluated.
resultsOf the patients, 138 (61.3%) were male and 87 (38.7%) were female. According to the distribution of the ABO system, blood group A was present in 109 (48.4%) patients, B in 33 (14.7%), AB in 20 (8.9%), and O in 63 (28%). Signet ring cell carcinoma, antrum tumor localization, and distant metastasis were more common in blood groups A and O. According to both the univariate and multivariate analyses, overall survival (OS) was statistically worse in patients with signet ring cell carcinoma and peritoneal metastasis (p < 0.05). The OS rate was the worst in blood group A and best in blood groups AB and B.
conclusionIn this study, blood group A presented as both a risk factor and a poor prognostic factor in the development of metastatic gastric cancer. In addition, signet ring cell histopathology and presence of metastasis were found to be more common in patients with blood group A and associated with a poor prognosis. Blood groups are inexpensive, easily available, and reliable parameters that can provide an idea about both prognosis and survival in gastric cancer. Therefore, they can serve as a guide for clinicians in the follow-up and evaluation of the prognosis of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.